SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.25 Insider Own3.70% Shs Outstand87.25M Perf Week-3.45%
Market Cap5.86B Forward P/E- EPS next Y-3.39 Insider Trans0.12% Shs Float83.77M Perf Month-10.25%
Income-356.60M PEG- EPS next Q-1.16 Inst Own83.50% Short Float5.77% Perf Quarter-6.48%
Sales765.80M P/S7.65 EPS this Y27.50% Inst Trans1.64% Short Ratio6.25 Perf Half Y-12.13%
Book/sh9.82 P/B7.01 EPS next Y24.80% ROA-12.30% Target Price119.78 Perf Year-8.34%
Cash/sh23.65 P/C2.91 EPS next 5Y- ROE-52.10% 52W Range61.28 - 101.24 Perf YTD-23.55%
Dividend- P/FCF- EPS past 5Y1.30% ROI-17.90% 52W High-32.00% Beta1.28
Dividend %- Quick Ratio5.10 Sales past 5Y164.50% Gross Margin86.10% 52W Low12.34% ATR3.49
Employees840 Current Ratio5.60 Sales Q/Q43.50% Oper. Margin-38.80% RSI (14)43.92 Volatility4.12% 5.20%
OptionableYes Debt/Eq1.28 EPS Q/Q42.80% Profit Margin-46.60% Rel Volume0.83 Prev Close71.61
ShortableYes LT Debt/Eq1.28 EarningsMay 04 AMC Payout- Avg Volume773.05K Price68.84
Recom1.90 SMA20-1.43% SMA50-9.91% SMA200-14.17% Volume642,191 Change-3.87%
Apr-04-22Resumed Cantor Fitzgerald Overweight $140
Jan-05-22Reiterated Needham Buy $157 → $150
Dec-09-21Upgrade Oppenheimer Perform → Outperform $125
Nov-05-21Upgrade JP Morgan Neutral → Overweight $130
Sep-15-21Upgrade Guggenheim Neutral → Buy
Aug-05-21Upgrade JP Morgan Underweight → Neutral $92 → $87
Jun-15-21Initiated BTIG Research Buy $110
Apr-26-21Resumed Credit Suisse Neutral $72
Jan-12-21Downgrade Citigroup Buy → Neutral $215 → $108
Jan-11-21Downgrade UBS Buy → Neutral
Jan-08-21Downgrade Raymond James Outperform → Mkt Perform
Jan-08-21Downgrade Morgan Stanley Overweight → Equal-Weight $95
Jan-08-21Downgrade JP Morgan Overweight → Underweight $96
Nov-11-20Initiated Berenberg Hold
Oct-28-20Initiated UBS Buy $212
Aug-25-20Initiated Raymond James Outperform $200
Aug-20-20Downgrade Credit Suisse Outperform → Neutral $185 → $167
Mar-31-20Initiated Mizuho Buy $183
Nov-01-19Initiated Guggenheim Buy $183
Aug-21-19Reiterated Needham Buy $196 → $170
May-20-22 02:28PM  
May-10-22 10:56AM  
May-09-22 11:49AM  
May-05-22 09:31AM  
05:30AM  
May-04-22 05:25PM  
04:05PM  
08:30AM  
Apr-29-22 06:23PM  
Apr-27-22 03:03PM  
08:30AM  
Apr-07-22 04:04PM  
Mar-31-22 06:30PM  
11:30AM  
Mar-30-22 02:49PM  
Mar-16-22 01:30PM  
Mar-08-22 08:30AM  
Mar-02-22 04:30PM  
10:16AM  
Mar-01-22 05:55PM  
04:05PM  
Feb-28-22 06:17PM  
08:55AM  
Feb-22-22 08:30AM  
06:16AM  
Feb-03-22 05:38PM  
Feb-01-22 08:00AM  
Jan-31-22 06:15PM  
Jan-19-22 05:38PM  
Jan-17-22 11:27AM  
Jan-12-22 09:38AM  
Jan-11-22 10:22AM  
Jan-10-22 10:50AM  
Jan-06-22 08:32AM  
Dec-31-21 08:45PM  
10:30AM  
Dec-28-21 09:50AM  
Dec-27-21 10:15AM  
Dec-25-21 11:38AM  
Dec-23-21 11:57AM  
Dec-22-21 11:35AM  
10:27AM  
Dec-21-21 11:24AM  
06:53AM  
Dec-20-21 11:07AM  
Dec-17-21 01:38PM  
10:35AM  
10:06AM  
Dec-16-21 10:00AM  
09:38AM  
Dec-15-21 07:38PM  
11:16AM  
Dec-14-21 03:17PM  
02:41PM  
11:06AM  
Dec-13-21 11:38PM  
10:33AM  
Dec-10-21 10:21AM  
09:58AM  
08:44AM  
Dec-09-21 11:38AM  
09:13AM  
Dec-08-21 07:38PM  
07:38PM  
07:38PM  
Dec-03-21 03:30PM  
12:22PM  
11:31AM  
09:23AM  
Dec-02-21 10:13AM  
09:43AM  
Nov-30-21 06:17PM  
04:20PM  
10:41AM  
09:16AM  
Nov-29-21 10:00AM  
Nov-26-21 02:33PM  
08:46AM  
Nov-25-21 10:56AM  
Nov-23-21 11:08AM  
Nov-22-21 08:18PM  
11:23AM  
Nov-18-21 10:27AM  
Nov-17-21 10:07AM  
08:31AM  
08:30AM  
Nov-12-21 12:56PM  
10:53AM  
Nov-11-21 10:15AM  
Nov-10-21 09:54AM  
Nov-04-21 06:23PM  
10:08AM  
04:31AM  
Nov-03-21 05:25PM  
04:01PM  
Nov-02-21 04:30PM  
Oct-29-21 06:15PM  
Oct-27-21 08:30AM  
Oct-20-21 07:00AM  
Oct-19-21 09:25AM  
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BEHRENS M KATHLEENDirectorDec 15Option Exercise10.085,00050,400135,517Dec 16 08:00 PM
GRAY MARY ANNDirectorDec 10Option Exercise0.0096709,403Dec 14 08:02 PM
Rodino-Klapac LouiseHead of R&D, CSONov 24Buy79.333,780299,86765,678Nov 29 08:00 AM
INGRAM DOUGLAS SPresident & CEONov 17Buy79.9425,0262,000,578365,082Nov 17 06:24 PM